GR 38032F (GR-C507/75): a novel compound effective in the prevention of acute cisplatin-induced emesis.

No abstract is available for this paper.

• Publication year

  1989

• Venue

  Journal of Clinical Oncology

• Publication date

  1989-06-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1200/JCO.1989.7.6.700PMID 2523957
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• TWO KINDS OF TRYPTAMINE RECEPTOR

  1997cited by this paper
• The role of the abdominal visceral innervation and 5-hydroxytryptamine M-receptors in vomiting induced by the cytotoxic drugs cyclophosphamide and cis-platin in the ferret.

  1988cited by this paper
• The emetic activity of centrally administered cisplatin in cats and its antagonism by zacopride

  1988cited by this paper
• Dose-ranging evaluation of the serotonin antagonist GR-C507/75 (GR38032F) when used as an antiemetic in patients receiving anticancer chemotherapy.

  1988cited by this paper
• The management of chemotherapy-induced nausea and vomiting.

  1987cited by this paper
• Identification and distribution of 5-HT3 receptors in rat brain using radioligand binding

  1987cited by this paper
• First results with ICS 205-930 (5-HT3 receptor antagonist) in prevention of chemotherapy-induced emesis.

  1987cited by this paper
• The management of nausea and vomiting in clinical oncology.

  1987cited by this paper
• Prevention of emesis in patients receiving cytotoxic drugs by GR38032F, a selective 5-HT3 receptor antagonist.

  1987cited by this paper
• Proposals for the classification and nomenclature of functional receptors for 5-hydroxytryptamine.

  1986cited by this paper
• Consecutive dose-finding trials adding lorazepam to the combination of metoclopramide plus dexamethasone: improved subjective effectiveness over the combination of diphenhydramine plus metoclopramide plus dexamethasone.

  1985cited by this paper
• Metoclopramide: dose-related toxicity and preliminary antiemetic studies in children receiving cancer chemotherapy.

  1985cited by this paper
• Identification of serotonin M-receptor subtypes and their specific blockade by a new class of drugs

  1985cited by this paper
• Incidence, course, and severity of delayed nausea and vomiting following the administration of high-dose cisplatin.

  1985cited by this paper
• Cisplatin-induced vomiting eliminated by ablation of the area postrema in cats.

  1984cited by this paper
• Neuronal 5-HT receptors in the periphery.

  1984cited by this paper
• Methodologic issues in trials of antiemetics.

  1984cited by this paper
• Ultrastructural localization of monoamines and peptides in rat area postrema.

  1984cited by this paper
• Antiemetic therapy: a review of recent studies and a report of a random assignment trial comparing metoclopramide with delta-9-tetrahydrocannabinol.

  1984cited by this paper
• Comparison of the antiemetic effect of high-dose intravenous metoclopramide and high-dose intravenous haloperidol in a randomized double-blind crossover study.

  1984cited by this paper
• Cisplatin-induced vomiting eliminated by ablation of the area postrema in cats.

  1984cited by this paper
• Antiemetic efficacy of dexamethasone. Randomized, double-blind, crossover study with prochlorperazine in patients receiving cancer chemotherapy.

  1984cited by this paper
• Antiemetic efficacy of dexamethasone therapy in patients receiving cancer chemotherapy.

  1983cited by this paper
• Neuropharmacology of Chemotherapy-induced Emesis

  1983cited by this paper
• Decreased cisplatin-induced nausea and vomiting with chronic alcohol ingestion.

  1983cited by this paper
• Nausea and Vomiting as Major Complications of Cancer Chemotherapy

  1983cited by this paper
• Extrapyramidal reactions with high-dose metoclopramide.

  1983cited by this paper
• Cisplatin-induced emesis in the Ferret: a new animal model.

  1982cited by this paper
• Prevalence and correlates of anticipatory nausea and vomiting in chemotherapy patients.

  1982cited by this paper
• Antiemetic efficacy of high-dose metoclopramide: randomized trials with placebo and prochlorperazine in patients with chemotherapy-induced nausea and vomiting.

  1981cited by this paper
• A comparison of the antiemetic effects of droperidol and prochlorperazine in chemotheray with cis-platinum.

  1980cited by this paper
• Multiple serotonin receptors: differential binding of [3H]5-hydroxytryptamine, [3H]lysergic acid diethylamide and [3H]spiroperidol.

  1979cited by this paper
• Antiemetic effect of delta-9-tetrahydrocannabinol in patients receiving cancer chemotherapy.

  1975cited by this paper
• Nonparametric Statistical Methods: Hollander/Nonparametric Statistical Methods

  1973cited by this paper
• Chi-square tests with one degree of freedom

  1963cited by this paper
• Principles and procedures of statistics.

  1961cited by this paper

• PREVENÇÃO DE NÁUSEAS E VÔMITOS NO PÓS-OPERATÔRIO DE CIRURGIA PLÁSTICA: ESTUDO COMPARATIVO ENTRE ON DANSETROM, METOCLOPRAMI DA E PLACEBO

  2013cites this paper
• Consensus recommendations for the prevention of vomiting and nausea following high-emetic-risk chemotherapy

  2011cites this paper
• Palonosetron hydrochloride for the prevention of chemotherapy-induced nausea and vomiting

  2010cites this paper
• Cisplatin-induced emesis: systematic review and meta-analysis of the ferret model and the effects of 5-HT3 receptor antagonists

  2010cites this paper
• Management der Chemotherapie-induzierten Emesis: Was ist Standard nach 20 Jahren klinischer Forschung?

  2009cites this paper
• Chemotherapy-induced nausea and vomiting.

  2008cites this paper
• A History of Drug Discovery

  2008cites this paper
• The Discovery, Use and Impact of Platinum Salts as Chemotherapy Agents for Cancer, vol. 30.

  2007cites this paper
• Gastrointestinal toxicity of chemotherapeutic agents.

  2006cites this paper
• Innovative approaches in the treatment of emesis

  2005cites this paper
• Consensus proposals for the prevention of acute and delayed vomiting and nausea following high-emetic-risk chemotherapy

  2005cites this paper
• Granisetron Plus Dexamethasone Versus Granisetron Alone in the Prevention of Vomiting Induced by Conditioning for Stem Cell Transplantation: A prospective Randomized Study

  2003cites this paper
• Cost-effectiveness of antiemetics use during cancer chemotherapy

  2003cites this paper
• Clinical assessment of ramosetron HCl oral preparation in the treatment of nausea and vomiting induced by cisplatin: A multicenter, randomized, parallel-design, double-blind comparative study with ondansetron HCl

  2002cites this paper
• Oral formulations of the selective serotonin3 antagonists ramosetron (intraoral disintegrator formulation) and granisetron hydrochloride (standard tablet) in treating acute chemotherapy-induced emesis, nausea, and anorexia: A multicenter, randomized, single-blind, crossover, comparison study

  2002cites this paper
• Barostat Examination of Proximal Site of the Anastomosis in Patients with Rectal Cancer after Low Anterior Resection

  2001cites this paper
• Barostat Examination of Proximal Site of the Anastomosis in Patients with Rectal Cancer after Low Anterior Resection

  2001cites this paper
• Comparison of the selective serotonin3 antagonists ramosetron and granisetron in treating acute chemotherapy-induced emesis, nausea, and anorexia: a single-blind, randomized, crossover study

  2000cites this paper
• Advances in use of the 5-HT3 receptor antagonists

  2000cites this paper
• Prophylaxis and Therapy of Postoperative Nausea and Vomiting

  1999cites this paper
• Efficacy of ondansetron in prophylaxis of postoperative nausea and vomiting in patients following infratentorial surgery: a placebo-controlled prospective double-blind study.

  1999cites this paper
• Tropisetron or ondansetron compared with placebo for prevention of postoperative nausea and vomiting.

  1998cites this paper
• Consensus Proposal for 5-HT3 Antagonists in the Prevention of Acute Emesis Related to Highly Emetogenic Chemotherapy

  1998cites this paper
• Single-dose oral granisetron has equivalent antiemetic efficacy to intravenous ondansetron for highly emetogenic cisplatin-based chemotherapy.

  1998cites this paper
• Methodology of antiemetic trials: response assessment, evaluation of new agents and definition of chemotherapy emetogenicity

  1998cites this paper
• [Management of chemotherapy-induced emesis: what is the standard after 20 years of clinical research].

  1998cites this paper
• Navoban (tropisetron, ICS 205-930) and dexamethasone combination in the prevention of vomiting for patients receiving preconditioning high-dose chemotherapy before marrow transplantation.

  1998cites this paper
• Consensus proposal for 5HT3 antagonists in the prevention of acute emesis related to highly emetogenic chemotherapy

  1998cites this paper
• Prevention of acute emesis in cancer patients following high-dose cisplatin with the combination of oral dolasetron and dexamethasone.

  1997cites this paper
• Effects of the 5-HT3 Antagonist, Ondansetron, on the Behavioral and Physiological Effects of Pentagastrin in Patients with Panic Disorder and Social Phobia

  1997cites this paper
• Granisetron in the prevention of vomiting induced by conditioning for stem cell transplantation: a prospective randomized study.

  1996cites this paper
• Prevention of Acute Cisplatin-Induced Nausea and Vomiting

  1996cites this paper
• Ondansetron: reasons to be restrictive.

  1996cites this paper
• Optimal control of acute cisplatin-induced emesis.

  1996cites this paper
• Antiemetic Drugs: Essential Pharmacology

  1996cites this paper
• Prevention of Highly Emetogenic Chemotherapy-Induced Vomiting: A Double Blind, Randomized Crossover Study to Compare Pancopride (LAS 30451) and Pancopride plus Dexamethasone

  1995cites this paper
• Preventing chemotherapy-induced nausea and vomiting: an update and a review of emesis.

  1995cites this paper
• Cost effectiveness of 5‐hydroxytryptamine3 receptor antagonists: a retrospective comparison of ondansetron and granisetron

  1995cites this paper
• Progress in reducing nausea and emesis. Comparisons of ondansetron (zofran), granisetron (kytril), and tropisetron (navoban)

  1995cites this paper
• The clinical use of ondansetron. New South Wales Therapeutic Assessment Group.

  1995cites this paper
• Dose-ranging evaluation of the serotonin antagonist dolasetron mesylate in patients receiving high-dose cisplatin.

  1994cites this paper
• Importance of nausea

  1994cites this paper
• Evaluation of butorphanol and cyproheptadine for prevention of cisplatin-induced vomiting in dogs.

  1994cites this paper
• Antiemetics in cancer chemotherapy: historical perspective and current state of the art

  1994cites this paper
• A Randomized Double‐Blind Trial of Ondansetron Alone Versus in Combination with Dexamethasone Versus in Combination with Dexamethasone and Lorazepam in the Prevention of Emesis Due to Cisplatin‐Based Chemotherapy

  1994cites this paper
• Cisplatin-induced peptic ulcers, vagotomy, adrenal and calcium modulation.

  1994cites this paper
• Control of Nausea and Vomiting by Granisetron in Ovarian Cancer Patients Treated with Different Cisplatin-Based Regimens

  1994cites this paper
• Anaphylactoid Reactions Associated with Ondansetron

  1994cites this paper
• 5-ht3 antagonist ondansetron for the treatment of chemotherapy-induced nausea and vomiting in an outpatient population.

  1994cites this paper
• Pharmacoeconomic analysis of ondansetron versus metoclopramide for cisplatin-induced nausea and vomiting.

  1994cites this paper
• [Antiemetic treatment and chemotherapy: general review].

  1994cites this paper
• Randomized Phase II Trial Comparing Two Versus Three Doses of Ondansetron When Used in Combination with Dexamethasone in Patients Receiving Cisplatin ≥100 mg/m2

  1994cites this paper
• Traitement antiémétique et chimiothérapie : revue générale

  1994cites this paper
• On‐demand antiemetic treatment with the serotonine antagonist tropisetron in cisplatin‐treated cancer patients

  1994cites this paper
• Efficacy and safety of granisetron, a selective 5-hydroxytryptamine-3 receptor antagonist, in the prevention of nausea and vomiting induced by high-dose cisplatin.

  1994cites this paper
• Adverse Effects Associated with Dexamethasone, Lorazepam, and Granisetron

  1994cites this paper
• Progress in controlling emesis with cancer chemotherapy

  1993cites this paper
• Methodological issues in antiemetic studies

  1993cites this paper
• Dose‐ranging antiemetic evaluation of the serotonin antagonist tropisetron in patients receiving anti‐cancer chemotherapy

  1993cites this paper
• Ondansetron.

  1993cites this paper
• Enhancing the effectiveness of the specific serotonin antagonists. Combination antiemetic therapy with dexamethasone

  1993cites this paper
• Antiemetic Activity of Oral Lorazepam in Addition to Methylprednisolone and Metoclopramide in the Prophylactic Treatment of Vomiting Induced by Cisplatin. A Double-Blind, Placebo-Controlled Study with Crossover Design

  1993cites this paper
• Phase II Trial of a Single Intravenous Dose of Ondansetron in Patients Receiving Cisplatin ≥ 100 mg/m2

  1993cites this paper
• Current issues in the management of nausea and vomiting.

  1993cites this paper
• Control of emesis associated with cancer chemotherapy.

  1993cites this paper
• Ondansetron plus dexamethasone in the control of high dose cisplatin-induced emesis.

  1993cites this paper
• Ondansetron versus chlorpromazine for preventing emesis in bone marrow transplant recipients: a double-blind randomized study.

  1993cites this paper
• Cisplatinum based chemotherapy: role of the antiserotoninergic ondansetron in prevention of emesis.

  1993cites this paper
• Reducing Chemotherapy-Induced Nausea and Vomiting

  1993cites this paper
• Control of chemotherapy-induced emesis.

  1993cites this paper
• Tropisetron (ICS 205-930): a selective 5-hydroxytryptamine antagonist.

  1993cites this paper
• Delayed emesis following high-dose cisplatin: a double-blind randomised comparative trial of ondansetron (GR 38032F) versus placebo.

  1993cites this paper
• Ondansetron in the treatment of nausea and vomiting induced by chemotherapy

  1993cites this paper
• [Role of ondansetron in oncology].

  1993cites this paper
• Antimitotics in cancer chemotherapy

  1992cites this paper
• Myths and realities of antiemetic treatment.

  1992cites this paper
• Five-drug antiemetic combination for cisplatin chemotherapy.

  1992cites this paper
• Ondansetron: Indications and Applications in the Paediatric Intensive Care Unit

  1992cites this paper
• Phase II trials of ondansetron with high-dose cisplatin.

  1992cites this paper
• Gastrointestinal toxicity of chemotherapeutic agents.

  1992cites this paper
• Nausea and Vomiting

  1992cites this paper
• Rationale for combination antiemetic therapy and strategies for the use of ondansetron in combinations.

  1992cites this paper
• Antiemetic Prophylaxis in Patients Undergoing Bone Marrow Transplantation: The Role of Ondansetron

  1992cites this paper
• Ondansetron reduces chemotherapy induced nausea and vomiting refractory to standard antiemetics.

  1992cites this paper
• Comparative trials of ondansetron versus metoclopramide in the prevention of acute cisplatin-induced emesis.

  1992cites this paper
• Course, patterns, and risk-factors for chemotherapy-induced emesis in cisplatin-pretreated patients: a study with ondansetron.

  1992cites this paper
• Methodology and assessment in clinical anti-emetic research: a meta-analysis of outcome parameters.

  1992cites this paper
• A randomized trial of two doses of granisetron in the treatment of chemotherapy-induced emesis. Dutch results within a multinational study.

  1992cites this paper
• Stratified, randomized, double-blind comparison of intravenous ondansetron administered as a multiple-dose regimen versus two single-dose regimens in the prevention of cisplatin-induced nausea and vomiting.

  1992cites this paper
• Are granisetron and ondansetron equivalent in the clinic?

  1992cites this paper
• Efficacy of ondansetron against nausea and vomiting caused by dacarbazine‐containing chemotherapy

  1992cites this paper
• Serotonin antagonists: treatment of chemotherapy-induced emesis.

  1992cites this paper
• [5-HT3 antagonists in therapy of cystostatic drug-induced vomiting].

  1992cites this paper
• Postoperative Nausea and Vomiting: Its Etiology, Treatment, and Prevention

  1992cites this paper
• Ondansetron: pharmacology of a specific 5HT3-receptor antagonist.

  1992cites this paper
• Emesis as a Complication of Cancer Chemotherapy: Pathophysiology, Importance, and Treatment

  1992cites this paper
• Cisplatin neurotoxicity: the relationship between dosage, time, and platinum concentration in neurologic tissues, and morphologic evidence of toxicity.

  1992cites this paper
• [Ondansetron--the first highly selective 5-HT3 antagonist in therapy of psychiatric diseases].

  1992cites this paper
• Review article: 5‐hydroxytryptamine agonists and antagonists in the modulation of gastrointestinal motility and sensation: clinical implications

  1992cites this paper
• The effectiveness of a single intravenous dose of ondansetron.

  1992cites this paper